Výsledky vyhledávání - "Matthias Meergans"

Akademický článek

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Autor: Douglas L. Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L. Naylor

Publikováno v: Therapeutic Advances in Neurological Disorders, Vol 11 (2018)

Background: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing–rem

Externí odkaz: https://doaj.org/article/8dc73721ee4e4953a23109e4e4cc0c15

Zobrazit plný text záznamu

Consensus Statement of the Middle East, Africa, and Russia (MEAR) Region Expert Meeting on Utilizing Digital Technology in Patient Care and Medical Education (Preprint)

Autor: Majid Alabbood, Ahmed Hegazy, Amr Hassan, Anthony Picton, Averin Evgeny, Fadi Farhat, Fekraoui Boubekeur Saddik, Filippo De Lorenzo, Konstantin Ovsyannikov, Marouen Braham, Matthias Meergans, Salman Aljarallah, Umut Demirci, Rasha Tarif

BACKGROUND Digital technology and health solutions have redefined patient care and medical education, especially during the COVID-19 pandemic. Merck medical affairs in partnership with digital experts in the Middle East, Africa, and Russia (MEAR) reg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1384e0c9e70b7c971fd40c6818c9a24e
https://doi.org/10.2196/preprints.44038

Zobrazit plný text záznamu

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Autor: Qunming Dong, Douglas L. Arnold, Maria L. Naylor, Matthias Meergans, Shulian Shang

Publikováno v: Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Therapeutic Advances in Neurological Disorders

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eced89c5d1ce8fdb27bdc518b1647737
https://doaj.org/article/8dc73721ee4e4953a23109e4e4cc0c15

Zobrazit plný text záznamu

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

Autor: Ralf A. Linker, Hans-Peter Hartung, Achim Gass, Jens Wuerfel, Olof Harlin, Mathias Mäurer, Judith Haas, Matthias Meergans, Volker Limmroth, Tjalf Ziemssen, Antonios Bayas, Martin Stangel, Björn Tackenberg

Publikováno v: BMC Neurology

Background: Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activity with long-term stabilization. However, the benefits of the drug are countered by a risk of developing progressive multifocal leukoencephalopathy i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::011e9e248e1143b02959239fb23b03be
http://archiv.ub.uni-heidelberg.de/volltextserver/21506/

Zobrazit plný text záznamu

069 Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing-remitting multiple sclerosis (RRMS): subgroup analysis of advance

Autor: Jang Yun, Scott D. Newsome, Matthias Meergans, Douglas L. Arnold, Maria L. Naylor

Publikováno v: Journal of Neurology, Neurosurgery & Psychiatry. 89:A28.2-A28

IntroductionThe pivotal phase 3 ADVANCE study evaluated the efficacy of subcutaneous peginterferon beta-1a 125 mcg every 2 weeks in RRMS patients, approximately 45% of whom were newly diagnosed and had no prior disease-modifying therapy (DMT) use. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b291e15c2dd68b3751737847fbe9124
https://doi.org/10.1136/jnnp-2018-anzan.68

Zobrazit plný text záznamu

Downregulation of beta-adrenergic receptors by low density lipoproteins and its prevention by beta-adrenergic receptor antagonists

Autor: Dorothea I. Axel, M. Pfohl, Helmut Heinle, Matthias Meergans, Karl R. Karsch, Bernhard R. Brehm

Publikováno v: Cardiovascular research. 38(2)

Vasodilation by beta-adrenergic receptors of smooth muscle cells appears to be impaired early after the onset of hypercholesteremia. The aim of this study was to analyze the modulation of beta-adrenergic receptor density and adenylyl cyclase activity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55eb75114c66c109c141b7d364ba2e03
https://pubmed.ncbi.nlm.nih.gov/9709415

Zobrazit plný text záznamu

Study Design and First Results of a Non-Interventional Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya(R)) in Multiple Sclerosis Patients in Germany (PANGAEA) (P04.131)

Autor: Matthias Meergans, T. van Lokven, Tjalf Ziemssen, R. Kempke

Publikováno v: Neurology. 78:P04.131-P04.131

Objective: In order to investigate the safety and efficacy of fingolimod (Gilenya®) in everyday clinical practice, a 4000-patient national safety study is being conducted, in which pharmaco-economic data will also be collected (PANGAEA = P ost- A ut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4295ac0ef5221f1518d6dc65f84721c9
https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.131

Zobrazit plný text záznamu

Fingolimod (Gilenya(R)) in Combination with an SSRI or SNRI Antidepressant in Multiple Sclerosis Patients with Mild to Moderate Depression: Design of a Phase IIIb Study (REGAIN) (P01.135)

Autor: Matthias Meergans, Katrin Schuh, Antonios Bayas

Publikováno v: Neurology. 78:P01.135-P01.135

Objective: The primary endpoint is the safety and tolerability profile of the combination of an SSRI or SNRI antidepressant with fingolimod in MS patients (expanded disability status scale (EDSS) 0–6.5) who are suffering mild to moderate depression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3aae486ff6fbf0ee91acb3ed2fac9882
https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.135

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání